Immunotherapy plus chemo for early-stage HR+/HER2- breast cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests adding the immunotherapy drug serplulimab to standard chemotherapy for people with early-stage HR-positive, HER2-negative breast cancer. It aims to see if this combination can improve outcomes before surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- Your breast cancer must be HR-positive (hormone receptor-positive) and HER2-negative, with a Ki67 score of 20% or higher.
- Your tumor must be at least cT2 (2 cm or larger) or cT1c with spread to lymph nodes.
- You must have measurable tumors on imaging like ultrasound or MRI.
- Your organ function (heart, liver, kidneys, blood cells) must be adequate, with a heart pumping function (LVEF) of 55% or more.
- You must not have cancer that has spread to other parts of the body (metastatic) and you should not have had prior chemotherapy, hormone therapy, or immunotherapy for this cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of chemotherapy, an immunotherapy drug, and two different schedules of radiation before surgery for a common type of breast cancer. The goal is to find which radiation approach works better and to improve outcomes.
This trial tests adding anlotinib (a targeted therapy) and benmelstobart (an immunotherapy) to standard chemotherapy before surgery for a specific type of breast cancer. It may help shrink tumors and improve outcomes for patients whose tumors have certain markers.
This trial tests a new drug combination given before surgery for early-stage, hormone receptor-positive breast cancer. It aims to see if this approach can improve outcomes for patients with high-risk features.
This trial tests a combination of chemotherapy, immunotherapy, and targeted radiation given before surgery for a certain type of breast cancer. The goal is to see if this approach can shrink tumors and improve outcomes.
This trial tests whether adding an immunotherapy drug (toripalimab) to standard chemotherapy before surgery can help treat HR+/HER2- breast cancer. It is for women with early-stage breast cancer that has not spread to other parts of the body.
This trial tests adding an immunotherapy drug (serplulimab) to standard chemotherapy for early-stage HR+/HER2- breast cancer. The goal is to see if the combination works better than chemo alone before surgery.
Hear when a new HR+/HER2- Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.